Critical Care (Oct 2020)

Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider

  • Patrick M. Honore,
  • Leonel Barreto Gutierrez,
  • Luc Kugener,
  • Sebastien Redant,
  • Rachid Attou,
  • Andrea Gallerani,
  • David De Bels

DOI
https://doi.org/10.1186/s13054-020-03294-7
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 2

Abstract

Read online

No abstracts available.